Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine.
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1032-1037. doi: 10.5588/ijtld.20.0386.
To evaluate the clinical features of disease progression among patients with COVID-19 to help early identification of patients at high risk. This was a retrospective, multi-centre cohort study. From 10 January to 29 February 2020, all cases diagnosed with COVID-19 at 24 hospitals (with complete medical records) in Jiangsu Province, China were recruited. The primary outcome was deterioration in condition, i.e., the dramatic progression from asymptomatic or mild or moderate status into severe or critically ill status during 14 days´ follow-up. Of the 625 patients in Jiangsu, none died; 597 patients were asymptomatic or had mild or moderate disease on admission, of whom 36 (6%) experienced disease deterioration to become severe or critically ill. Disease deterioration to severe or critically ill status was associated with age, pulmonary opacity score, lymphocyte count on admission and exposure to the pandemic centre in Wuhan.
评估 COVID-19 患者疾病进展的临床特征，以帮助早期识别高危患者。这是一项回顾性、多中心队列研究。2020 年 1 月 10 日至 2 月 29 日，在中国江苏省的 24 家医院（有完整病历）中，共招募了所有诊断为 COVID-19 的病例。主要结局是病情恶化，即在 14 天的随访期间，无症状或轻症或中度患者急剧进展为重症或危重症。在江苏的 625 名患者中，没有死亡病例；597 名患者入院时无症状或有轻度或中度疾病，其中 36 名（6%）病情恶化，成为重症或危重症。病情恶化至重症或危重症状态与年龄、肺部混浊评分、入院时的淋巴细胞计数以及接触武汉的疫情中心有关。
